You have no items in your shopping cart.
Description
Research Area
Images & Validation
−
| Application Notes |
|---|
Key Properties
−| Expression System | HEK293 Cells |
|---|---|
| Biological Origin | Human |
| Biological Activity | Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessels and endothelial cell growth, increasing microvascular permeability, promoting cell migration and inhibiting apoptosis. Alternatively spliced transcript variants of VEGF-A encod either secreted or cell-associated isoforms. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
| Tag | C-6xHis |
| Expression Region | Ala27-Arg147 |
| MW | 16-18 KDa (reducing condition) |
| Purity | SDS-PAGE: > 99.9%; SEC-HPLC: 97.75% |
| Protein Sequence | Ala27-Arg147 |
Storage & Handling
−| Storage | -20°C |
|---|---|
| Expiration Date | 6 months from date of receipt. |
| Disclaimer | For research use only |
Similar Products
−VEGF121 Protein, Human, Recombinant (His & Avi), Biotinylated [orb1960084]
98.00%
17 kDa (predicted). Due to glycosylation, the protein migrates to 18 kDa and 22-25 kDa under reduced (R) condition, 30 kDa and 32-40 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
500 μg, 100 μg, 1 mgVEGF121 Protein, Human, Recombinant (His & Avi) [orb1960085]
98.00%
17 kDa (predicted). Due to glycosylation, the protein migrates to 18 kDa and 22-25 kDa under reduced (R) condition, 30 kDa and 32-40 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
500 μg, 100 μg, 1 mgVEGF165 Protein, Human, Recombinant (His & Avi) [orb1960086]
> 95%
22.2 kDa (predicted). Due to glycosylation, the protein migrates to 28-35 kDa under reduced (R) condition, 45-60 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
1 mg, 100 μg, 500 μgVEGF165 Protein, Human, Recombinant (His & Avi), FITC-Labeled [orb1960087]
> 95%
22.2 kDa (predicted). Due to glycosylation, the protein migrates to 28-33 kDa under reduced (R) condition, 45-55 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
1 mg, 500 μg, 100 μg

Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].